140 related articles for article (PubMed ID: 19089844)
1. PEL: an unbiased method for estimating age-dependent genetic disease risk from pedigree data unselected for family history.
Alarcon F; Bourgain C; Gauthier-Villars M; Planté-Bordeneuve V; Stoppa-Lyonnet D; Bonaïti-Pellié C
Genet Epidemiol; 2009 Jul; 33(5):379-85. PubMed ID: 19089844
[TBL] [Abstract][Full Text] [Related]
2. A nonparametric method for penetrance function estimation.
Alarcon F; Bonaïti-Pellié C; Harari-Kermadec H
Genet Epidemiol; 2009 Jan; 33(1):38-44. PubMed ID: 18618769
[TBL] [Abstract][Full Text] [Related]
3. Estimating penetrance from family data using a retrospective likelihood when ascertainment depends on genotype and age of onset.
Carayol J; Bonaïti-Pellié C
Genet Epidemiol; 2004 Sep; 27(2):109-17. PubMed ID: 15305327
[TBL] [Abstract][Full Text] [Related]
4. Correcting for ascertainment bias of relative-risk estimates obtained using affected-sib-pair linkage data.
Cordell HJ; Olson JM
Genet Epidemiol; 2000 Apr; 18(4):307-21. PubMed ID: 10797591
[TBL] [Abstract][Full Text] [Related]
5. ARCAD: a method for estimating age-dependent disease risk associated with mutation carrier status from family data.
Le Bihan C; Moutou C; Brugières L; Feunteun J; Bonaïti-Pellié C
Genet Epidemiol; 1995; 12(1):13-25. PubMed ID: 7713397
[TBL] [Abstract][Full Text] [Related]
6. Risks of cancer due to a single BRCA1 mutation in an extended Utah kindred.
Vogl FD; Badzioch MD; Steele L; Neuhausen SL; Goldgar DE
Fam Cancer; 2007; 6(1):63-71. PubMed ID: 17051349
[TBL] [Abstract][Full Text] [Related]
7. BRCA1 and BRCA2 mutation predictions using the BOADICEA and BRCAPRO models and penetrance estimation in high-risk French-Canadian families.
Antoniou AC; Durocher F; Smith P; Simard J; Easton DF;
Breast Cancer Res; 2006; 8(1):R3. PubMed ID: 16417652
[TBL] [Abstract][Full Text] [Related]
8. Optimal designs for estimating penetrance of rare mutations of a disease-susceptibility gene.
Gong G; Whittemore AS
Genet Epidemiol; 2003 Apr; 24(3):173-80. PubMed ID: 12652521
[TBL] [Abstract][Full Text] [Related]
9. A pedigree analysis with minimised ascertainment bias shows anticipation in Met30-transthyretin related familial amyloid polyneuropathy.
Yamamoto K; Ikeda S; Hanyu N; Takeda S; Yanagisawa N
J Med Genet; 1998 Jan; 35(1):23-30. PubMed ID: 9475090
[TBL] [Abstract][Full Text] [Related]
10. Genetic anticipation in BRCA1/BRCA2 families after controlling for ascertainment bias and cohort effect.
Guindalini RS; Song A; Fackenthal JD; Olopade OI; Huo D
Cancer; 2016 Jun; 122(12):1913-20. PubMed ID: 26992017
[TBL] [Abstract][Full Text] [Related]
11. On the use of familial aggregation in population-based case probands for calculating penetrance.
Begg CB
J Natl Cancer Inst; 2002 Aug; 94(16):1221-6. PubMed ID: 12189225
[TBL] [Abstract][Full Text] [Related]
12. Genetic study of transthyretin amyloid neuropathies: carrier risks among French and Portuguese families.
Planté-Bordeneuve V; Carayol J; Ferreira A; Adams D; Clerget-Darpoux F; Misrahi M; Said G; Bonaïti-Pellié C
J Med Genet; 2003 Nov; 40(11):e120. PubMed ID: 14627687
[No Abstract] [Full Text] [Related]
13. Evidence for further breast cancer susceptibility genes in addition to BRCA1 and BRCA2 in a population-based study.
Antoniou AC; Pharoah PD; McMullan G; Day NE; Ponder BA; Easton D
Genet Epidemiol; 2001 Jul; 21(1):1-18. PubMed ID: 11443730
[TBL] [Abstract][Full Text] [Related]
14. Breast cancer risk assessment: use of complete pedigree information and the effect of misspecified ages at diagnosis of affected relatives.
Schmidt S; Becher H; Chang-Claude J
Hum Genet; 1998 Mar; 102(3):348-56. PubMed ID: 9544851
[TBL] [Abstract][Full Text] [Related]
15. Contribution of BRCA1 and BRCA2 germ-line mutations to the incidence of breast cancer in young women: results from a prospective population-based study in France.
Bonadona V; Sinilnikova OM; Chopin S; Antoniou AC; Mignotte H; Mathevet P; Brémond A; Martin A; Bobin JY; Romestaing P; Raudrant D; Rudigoz RC; Léoné M; Chauvin F; Easton DF; Lenoir GM; Lasset C
Genes Chromosomes Cancer; 2005 Aug; 43(4):404-13. PubMed ID: 15887246
[TBL] [Abstract][Full Text] [Related]
16. A log-linear model for binary pedigree data.
Hopper JL; Derrick PL
Genet Epidemiol Suppl; 1986; 1():73-82. PubMed ID: 3471672
[TBL] [Abstract][Full Text] [Related]
17. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies.
Antoniou A; Pharoah PD; Narod S; Risch HA; Eyfjord JE; Hopper JL; Loman N; Olsson H; Johannsson O; Borg A; Pasini B; Radice P; Manoukian S; Eccles DM; Tang N; Olah E; Anton-Culver H; Warner E; Lubinski J; Gronwald J; Gorski B; Tulinius H; Thorlacius S; Eerola H; Nevanlinna H; Syrjäkoski K; Kallioniemi OP; Thompson D; Evans C; Peto J; Lalloo F; Evans DG; Easton DF
Am J Hum Genet; 2003 May; 72(5):1117-30. PubMed ID: 12677558
[TBL] [Abstract][Full Text] [Related]
18. BRCA1, BRCA2 and TP53 mutations in very early-onset breast cancer with associated risks to relatives.
Lalloo F; Varley J; Moran A; Ellis D; O'dair L; Pharoah P; Antoniou A; Hartley R; Shenton A; Seal S; Bulman B; Howell A; Evans DG
Eur J Cancer; 2006 May; 42(8):1143-50. PubMed ID: 16644204
[TBL] [Abstract][Full Text] [Related]
19. Founder BRCA1 and BRCA2 mutations in Ashkenazi Jews in Israel: frequency and differential penetrance in ovarian cancer and in breast-ovarian cancer families.
Levy-Lahad E; Catane R; Eisenberg S; Kaufman B; Hornreich G; Lishinsky E; Shohat M; Weber BL; Beller U; Lahad A; Halle D
Am J Hum Genet; 1997 May; 60(5):1059-67. PubMed ID: 9150153
[TBL] [Abstract][Full Text] [Related]
20. Prevalence and penetrance of BRCA1 and BRCA2 mutations in a population-based series of breast cancer cases. Anglian Breast Cancer Study Group.
Anglian Breast Cancer Study Group
Br J Cancer; 2000 Nov; 83(10):1301-8. PubMed ID: 11044354
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
